Compare Adaptive Biotechnologies Corp (ADPT) vs Wix.Com Ltd (WIX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Wix.Com Ltd — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while Wix.Com Ltd trades at $47.52 (market cap $2.11B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Wix.Com Ltd nearer its low. Which is the better fit depends on your goals.
| ADPT | WIX | |
|---|---|---|
Market Cap | $3.33B | $2.11B |
Sector | Health | Technology |
52-Week High | $22.37 | $184.24 |
52-Week Low | $10.24 | $40.43 |
Enterprise Value | $3.19B | $1.67B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
WIX trades at $50.36, up 2.05% today, amid mixed signals. The stock shows strong revenue growth, reaching $1.99B in 2025, but profitability remains inconsistent with a net margin of -1.97%. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026. Technical indicators are bullish overall, with RSI suggesting mild overbought conditions. Positive news includes partnerships with Elavon and Microsoft, though legal investigations pose headwinds.
Outlook: Analyst consensus is bullish with a $83.13 price target, but risks include legal scrutiny and volatile earnings. Investment opportunity lies in revenue growth and strategic partnerships, countered by profitability challenges and potential legal liabilities. Near-term performance hinges on Q2 2026 earnings and resolution of investigations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
